GlassScriptPhysician profile
Paul Bruce Kuder
NPI 1801567367
$8,030.82
in general payments reported to CMS, 2019-2025
25 companies · $2,955 in 2025
The $2,955 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.14 · 2022: $1,293 · 2023: $1,763 · 2024: $2,002 · 2025: $2,955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,637 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,636.59 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,196.17 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,097.23 | 2022-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $920.35 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $504.59 | 2022-2025 | Stelara, Tremfya, Simponi |
| Regeneron Healthcare Solutions, INC. | $454.15 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $444.70 | 2021-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $307.54 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $288.05 | 2022-2024 | Dificid, Zinplava |
| Gilead Sciences, INC. | $264.87 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $240.58 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $223.73 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $217.65 | 2024-2025 | Zenpep, Vowst |
| Ardelyx, INC. | $190.59 | 2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $189.36 | 2022-2023 | Ocaliva |
| Celgene Corporation | $107.10 | 2022-2024 | Zeposia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $85.79 | 2023-2024 | Bravo, Gi Genius |
| Alexion Pharmaceuticals, INC. | $73.30 | 2022 | |
| Pfizer INC. | $55.50 | 2022 | |
| Lilly USA, LLC | $36.46 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $36.21 | 2023-2025 | Rebyota |
| Nestle Healthcare Nutrition INC. | $32.96 | 2023 | |
| Organon LLC | $18.33 | 2023 | Hadlima, Renflexis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.19 | 2023 | Cyltezo |
| Daiichi Sankyo INC. | $15.76 | 2024 | Injectafer |
| Sandoz INC. | $13.66 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Kuder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.